MIN-117: Completed Phase IIa enrollment

Minerva completed enrollment of 84 patients in a double-blind, placebo-controlled, European Phase IIa trial comparing 0.5 and 2.5 mg oral MIN-117 daily vs. 20 mg oral paroxetine daily. Minerva has exc...